Amounts owed under license agreement.

No definition available.

Name:	dnth_AmountsOwedUnderLicenseAgreement
Namespace Prefix:	dnth_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Payment of annual license fees and annual antibody program fees.

+ References

No definition available.

+ Details

Name:	dnth_PaymentOfAnnualLicenseFeesAndAnnualAntibodyProgramFees
Namespace Prefix:	dnth_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Potential development regulatory and sales based milestone payments due.

+ References

No definition available.

+ Details

Name:	dnth_PotentialDevelopmentRegulatoryAndSalesBasedMilestonePaymentsDue
Namespace Prefix:	dnth_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The potential amount of milestone payments due upon achievement of specified targets.

+ References

No definition available.

+ Details

Name:	dnth_PotentialMilestonePaymentsDue
Namespace Prefix:	dnth_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Upfront and near term milestone payments due.

+ References

No definition available.

+ Details

Name:	dnth_UpfrontAndNearTermMilestonePaymentsDue
Namespace Prefix:	dnth_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Upfront payments due.

+ References

No definition available.

+ Details

Name:	dnth_UpfrontPaymentsDue
Namespace Prefix:	dnth_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=dnth_LeadsLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=dnth_DevelopmentMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dnth_AlloyTherapeuticsLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dnth_FirstSelectedAntibodyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=dnth_CommercialMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=dnth_MilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dnth_IontasLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dnth_FirstDevelopmentProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dnth_SecondDevelopmentProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies - Additional Information (Details) $ in Thousands, £ in Millions	3 Months Ended
	Mar. 31, 2026 USD ($)	Mar. 31, 2025 USD ($)	Mar. 31, 2026 GBP (£)	Oct. 16, 2025 USD ($)
Other Commitments [Line Items]
Research and development expense	$ 34,528	$ 27,003
Leads License Agreement [Member]
Other Commitments [Line Items]
Upfront payment due				$ 38,000
Upfront and near-term milestone payments due	30,000			30,000
Potential milestone payments due				8,000
Research and development expense	100
Leads License Agreement [Member] \| Development Milestone [Member]
Other Commitments [Line Items]
Development and regulatory approval and sales based milestone due				$ 962,000
Alloy Therapeutics Llc [Member]
Other Commitments [Line Items]
Payment of annual license fees and program fees	50
Alloy Therapeutics Llc [Member] \| Development Milestone [Member] \| First Selected Antibody [Member] \| Maximum [Member]
Other Commitments [Line Items]
Potential milestone payments due	1,800
Alloy Therapeutics Llc [Member] \| Commercial Milestone [Member] \| First Selected Antibody [Member] \| Maximum [Member]
Other Commitments [Line Items]
Potential milestone payments due	11,000
Alloy Therapeutics Llc [Member] \| Milestone Payments [Member]
Other Commitments [Line Items]
Amounts owed under license agreement	0	0
IONTAS Limited [Member] \| Development Milestone [Member] \| First Development Program [Member]
Other Commitments [Line Items]
Potential milestone payments due	4,100		£ 3.1
IONTAS Limited [Member] \| Development Milestone [Member] \| Second Development Program [Member]
Other Commitments [Line Items]
Potential milestone payments due	3,300		2.5
IONTAS Limited [Member] \| Commercial Milestone [Member] \| First Development Program [Member]
Other Commitments [Line Items]
Potential milestone payments due	3,000		£ 2.3
IONTAS Limited [Member] \| Milestone Payments [Member]
Other Commitments [Line Items]
Research and development expense	$ 200	$ 200